
Please try another search
ContraFect (NASDAQ:CFRX) Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin...
ContraFect (CFRX) Resumes Trading Following Pause, Up 84%
Benzinga - ContraFect Corporation (NASDAQ: CFRX) has announced the database lock of its Phase 3 DISRUPT study of exebacase in patients with Staph aureus bacteremia, along with a summary of topline...
Investing.com - ContraFect Corp reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations. ContraFect Corp announced earnings per share...
ContraFect Corporation (NASDAQ: CFRX) said it continues to advance lead programs toward new clinical studies and expects to file with regulatory authorities later this year to initiate a study of...
Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Technology, Utilities and Consumer Services sectors propelled shares higher while losses in the Basic Materials, Oil...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novavax Receives Much Awaited FDA Nod For Protein-Based COVID-19 Vaccine The FDA granted emergency use...
Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Healthcare, Consumer Goods and Technology sectors propelled shares higher while losses in the Basic Materials, Telecoms...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Telecoms, Industrials and Utilities sectors propelled shares higher. At the close in NYSE, the Dow Jones Industrial...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review